AFT Pharmaceuticals and its NBR Rich Lister-founder will “vigorously defend” allegations they went against the interests of a subsidiary’s minority shareholder in pursuing a drug development opportunity that was not open to them.
The dual-listed drug developer told the NZX a lawsuit had
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
